CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 554 enrolled
Drug / intervention
Deplin®other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01369030
NCT01369030N/ACompleted
CompareCT.gov

Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)

Pamlab, Inc.·observational·Posted Jun 8, 2011·Updated Jun 3, 2014

In Brief

An observational study evaluating Deplin® for Major Depressive Disorder. Completed, enrolled 554 participants across 2 sites.

Detailed Summary

This study will be an observational study in which patients who have been prescribed Deplin® are invited to participate in surveys regarding their experiences with Deplin®. The purpose of this study is to increase the understanding of the role of L-methylfolate among patients who are candidates for Deplin®, provide patients with personalized education and support, and contribute to the overall understanding of the needs and concerns of patients being treated for depression.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
CollaboratorsInfoMedics, Inc.

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 8, 2011
Enrollment StartNov 1, 2010
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.1 years ago

Interventions

Deplin®other

Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.